Skip to main content
OpenTrials
Completed

NCT Number: NCT03341949

Soluble CD146 and Proteinuria in Chronic Renal Disease

Chronic renal disease (CKD) is defined as a decrease in glomerular filtration rate (GFR) and / or proteinuria or albuminuria (a protein present in urine). Albuminuria is considered a marker of endothelial dysfunction. Proteinuria and / or albuminuria are recognized as cardiovascular risk factors in both diabetic and non-diabetic populations, independently of GFR. It is also a marker of progression of kidney disease. cluster of differentiation 146 (CD146) is an endothelial adhesion molecule with preferential localization in the junction. Soluble CD146 (or CD146s). CD146s is a biomarker of endothelial dysfunction that is easy to assay. The increase in CD146 levels was described during the MRC, especially in diabetic patients with significant proteinuria. In two independent cohorts of patients with CDR, CD146s did not correlate with creatinine or GFR but appeared to correlate with proteinuria.

The aim of our study is to determine whether the blood concentration of CD146s is correlated with proteinuria independently of GFR. For this purpose, we propose this study in the kidney nephrology and transplantation center of Conception Hospital, with the objective of highlighting the link between proteinuria and serum CD146 levels in patients with CKD, whatever their renal function and / or underlying pathology. 205 patients will be included over two years with dosing of CD146s and proteinuria at the same time. These 205 patients will be recruited at each stage of the CKD (41 in each arm). CD146s could be a new biomarker predicting the risk of renal function impairment or cardiovascular risk independent of renal function.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult subject aged 18 years or over
  • Subject capable of giving informed consent
  • Patient with chronic kidney disease (stage 1 to 5 CKD regardless of etiology)

Exclusion criteria

  • Pregnant or lactating woman
  • Person deprived of liberty or hospitalized without consent
  • Major under legal protection or unable to express his consent
  • Refusal of the patient
  • Patient with a history of kidney transplantation
  • Evolutionary cancer

Treatment and study plan

Recurring blood sample

Biological

An additional tube will be collected for the assay of CD146s as part of the research

Primary outcomes

  1. Serum CD146s assay

    Time frame: 12 months

    determining the blood concentration of CD146s is correlated with proteinuria regardless of glomerular filtration rate (GFR).

  2. The dosage of proteinuria

    Time frame: 12 months

    determining the blood concentration of CD146s is correlated with proteinuria regardless of glomerular filtration rate (GFR).

Sponsors and collaborators

Lead sponsor

Assistance Publique Hopitaux De Marseille

Other

Registry information

Acronym: CPinMRC

Important dates

Study start
2018
Primary completion
2020
Study completion
2023
First posted
Nov 14, 2017
Registry last updated
May 30, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.